{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:43:31Z","timestamp":1760935411844,"version":"build-2065373602"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Diffuse large B-cell lymphoma (DLBCL), an aggressive subtype of non-Hodgkin lymphoma, exhibits heterogeneous clinical outcomes. While rituximab, a CD20 inhibitor, combined with chemotherapy has improved survival in some patients, resistance remains prevalent, particularly in hypoxic tumor microenvironments. Understanding hypoxia-related genes (HRGs) and their role in rituximab resistance is critical to addressing therapeutic challenges in high-risk DLBCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Gene expression profiles from GEO datasets (GSE56315: DLBCL tumor vs. normal; GSE104212: hypoxia-treated DLBCL cell lines) were analyzed to identify overlapping genes between DLBCL-signature genes (DSGs) and HRGs. protein interaction network topology analysis and Lasso regression modeling of TCGA-DLBC dataset were employed to screen regulator and hub genes. Hub genes linked to rituximab response and survival were validated in DLBCL patients receiving rituximab therapy. Functional enrichment analysis was used to explore associated pathways. The expression of the identified regulator and hub genes was validated using reverse transcription quantitative polymerase chain reaction (RT-qPCR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>58 overlapping genes were identified between DSGs and HRGs. PPI network and Lasso regression revealed 5 <jats:italic>MS4A1<\/jats:italic> regulator genes and 10 hub genes. Among these, <jats:italic>LGALS1<\/jats:italic> (HR = 0.588, <jats:italic>p<\/jats:italic> = 0.00085), <jats:italic>TIMP1<\/jats:italic> (HR = 0.591, <jats:italic>p<\/jats:italic> = 0.00098), <jats:italic>ANXA1<\/jats:italic> (HR = 0.614, p=0.0024) and <jats:italic>STAP1<\/jats:italic> (HR = 0.633, p=0.0035) were significantly associated with overall survival and <jats:italic>GPNMB<\/jats:italic> (AUC = 0.869), <jats:italic>CDCA7<\/jats:italic> (AUC = 0.686), and <jats:italic>STAP1<\/jats:italic> (AUC = 0.663) associated with treatment response in rituximab-treated patients. Functional analysis implicated these genes in B-cell receptor (BCR) and PI3K-AKT signaling pathways, suggesting their mechanistic roles in therapeutic resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study identifies hypoxia-associated genes critical to rituximab resistance in DLBCL, highlighting potential therapeutic targets. Their involvement in BCR and PI3K-AKT pathways underscores novel vulnerabilities for overcoming refractory disease. Our findings provide a foundation for developing strategies to improve outcomes in high-risk DLBCL patients with hypoxic microenvironments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1592441","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:33Z","timestamp":1760933673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling hypoxic regulatory networks by bioinformatics: mechanisms of hypoxia-related hub genes driving rituximab resistance and poor prognosis in DLBCL"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiayi","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zizhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1283214","article-title":"Treatment approaches of hard-to-treat non-Hodgkin lymphomas","volume":"10","author":"Nandagopal","year":"2017","journal-title":"Expert Rev Hematology."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.3390\/ijms21062081","article-title":"Drug resistance in non-hodgkin lymphomas","volume":"21","author":"Klener","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.adq4510","article-title":"Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy","volume":"387","author":"Ghosh","year":"2025","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-025-02341-y","article-title":"Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targeta ble with specific inhibitors","volume":"11","author":"Daumova","year":"2025","journal-title":"Cell Death Discov"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01277\/full","article-title":"Sustain, adapt, and overcome\u2014Hypoxia associated changes in the progression of lymphatic neoplasia","volume":"9","author":"Matolay","year":"2019","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41598-018-19182-8","article-title":"Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL","volume":"8","author":"Bhalla","year":"2018","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0360-1","article-title":"Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL","volume":"33","author":"Hohtari","year":"2019","journal-title":"Leukemia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.7080","article-title":"Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis","volume":"33","author":"Dybk\u00e6r","year":"2015","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2018.06.004","article-title":"The Bayesian adaptive lasso regression","author":"Alhamzawi","year":"2018","journal-title":"Math Biosci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12859-019-3036-6","article-title":"Measuring rank robustness in scored protein interaction networks","volume":"20","author":"Bozhilova","year":"2019","journal-title":"BMC Bioinf"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","article-title":"cytoHubba: identifying hub objects and sub-networks from complex interactome","author":"Chin","year":"2014","journal-title":"BMC Syst Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7788.76794","article-title":"Understanding survival analysis: Kaplan-Meier estimate","volume":"1","author":"Goel","year":"2010","journal-title":"Int J Ayurveda Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-085092","article-title":"PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma","volume":"111","author":"Leseux","year":"2008","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene."},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.intimp.2012.06.012","article-title":"Bucillamine inhibits CD40-mediated Akt activation and antibody production in mouse B-cell lymphoma","volume":"14","author":"Tsuji","year":"2012","journal-title":"Int Immunopharmacol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237537","article-title":"Rituximab inhibits B-cell receptor signaling","volume":"115","author":"Kheirallah","year":"2010","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"114541","DOI":"10.1016\/j.celrep.2024.114541","article-title":"Pre-B cell receptor acts as a selectivity switch for galectin-1 at the pre-B cell surface","volume":"43","author":"Touarin","year":"2024","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-681130","article-title":"Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms","volume":"127","author":"Lykken","year":"2016","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3942-9","article-title":"Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression","volume":"37","author":"Tang","year":"2016","journal-title":"Tumour Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2005.12.002","article-title":"Structure and function of matrix metalloproteinases and TIMPs","volume":"69","author":"Nagase","year":"2006","journal-title":"Cardiovasc Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63781-9","article-title":"Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"164","author":"Lai","year":"2004","journal-title":"Am J Pathol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100625","DOI":"10.1016\/j.mcpro.2023.100625","article-title":"Proteomics identifies circulating TIMP-1 as a prognostic biomarker for diffuse large B-cell lymphoma","volume":"22","author":"Lou","year":"2023","journal-title":"Mol Cell Proteomics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"111854","DOI":"10.1016\/j.intimp.2024.111854","article-title":"The role of ANXA1 in the tumor microenvironment","volume":"131","author":"Li","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2018.3887","article-title":"Silencing of Annexin A1 suppressed the apoptosis and inflammatory response of preeclampsia rat trophoblasts","volume":"42","author":"Feng","year":"2018","journal-title":"Int J Mol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.8998","article-title":"Overexpression of Annexin A1 protects against benzo[a]pyrene\u2212induced bronchial epithelium injury","volume":"18","author":"Cui","year":"2018","journal-title":"Mol Med Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02443-2","article-title":"GPNMB: a potent inducer of immunosuppression in cancer","volume":"41","author":"Lazaratos","year":"2022","journal-title":"Oncogene."},{"key":"B35","doi-asserted-by":"publisher","first-page":"108998","DOI":"10.1016\/j.abb.2021.108998","article-title":"GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt\/\u03b2-catenin signaling pathway","volume":"710","author":"Wang","year":"2021","journal-title":"Arch Biochem Biophys"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0793-7","article-title":"GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K\/AKT\/mTOR pathway signaling and \u03b2-catenin activity","volume":"38","author":"Maric","year":"2019","journal-title":"Oncogene."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6346","article-title":"GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K\/Akt\/mTOR signaling pathway","volume":"39","author":"Jin","year":"2018","journal-title":"Oncol Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188961","article-title":"CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth","volume":"103","author":"Jim\u00e9nez-","year":"2018","journal-title":"Haematologica."},{"key":"B39","doi-asserted-by":"publisher","first-page":"152559","DOI":"10.1016\/j.prp.2019.152559","article-title":"CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle","volume":"215","author":"Wang","year":"2019","journal-title":"Pathol Res Pract"},{"key":"B40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1128\/MCB.00276-12","article-title":"The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation","volume":"33","author":"Gill","year":"2013","journal-title":"Mol Cell Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41598-017-17704-4","article-title":"High STAP1 expression in DUX4-rearranged cases is not suit able as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Steeghs","year":"2018","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01387-9","article-title":"Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML","volume":"39","author":"Toda","year":"2020","journal-title":"Oncogene."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1592441\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:34Z","timestamp":1760933674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1592441\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":42,"alternative-id":["10.3389\/fonc.2025.1592441"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1592441","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1592441"}}